TP53 and cancer: Similarly, U7D1 (Figure 14) has been designed from the potent non-competitive USP7 inhibitor 2a (Figure 9) and demonstrated relevant inhibitory activity (IC50 = 6 nM) against cancer cells bearing p53 mutations non-sensitive to other USP7 inhibitors [194].